From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Sat, 22 Feb 2020 20:51:00 +0000

To: Stover, Kathy (NIH/NIAID) [E]

Cc: Billet, Courtney (NIH/NIAID) (E];Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg
(NIH/NIAID) [E]

Subject: RE: FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial
Attachments: NIAID press release COVID-19 treatment trial FOG - with fauci tracked
edits.docx

See my minor tracked edits. Thanks.

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone:

FAX: (301 456-4409
E-mail#__
The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectlous Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

  

From: Stover, Kathy (NIH/NIAID) [E]
Sent: Friday, February 21, 2020 3:55 PM

To: Fauci, Anthony (NIH/NIAID) (E] [Oy >

Cc: Billet, Courtney (NIH/NIAID) (EF) Conrad, Patricia (NIH/NIAID) [E]
Ce e>; Folkers, Greg (NIH/NIAID) [E] [2 OS G]>

Subject: FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial

 

 

Hi Dr. Fauci,

Please find attached for your review a draft press release to announce the launch of the
remdesivir COVID-19 treatment trial, which enrolled its first patient today. It’s been reviewed
by the following individuals/groups:

e FOG

e OCGR (Kathy Stover, Courtney Billet)

e DMID: Emily Erbelding, John Beigel

e DCR: Cliff Lane, Libby Higgs

e U Nebraska (Christopher Kratochvil, Andre Kalil, comms dept)

e Awaiting comments from Gilead and WHO.

NIH-001633
